Destiny Pharma PLC
LSE:DEST
Destiny Pharma PLC
LSE:DEST
Price:
16.25 GBX
Market Closed
Updated:
May 17, 2024
Destiny Pharma PLC
Income from Continuing Operations
|
Destiny Pharma PLC
Income from Continuing Operations Peer Comparison
Comparables:
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Destiny Pharma PLC
LSE:DEST
|
Income from Continuing Operations
-£6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Income from Continuing Operations
-$151.1m
|
CAGR 3-Years
-142%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Income from Continuing Operations
-$208.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Income from Continuing Operations
-$168.2m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£55.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£30.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
See Also
What is Destiny Pharma PLC's Income from Continuing Operations?
Income from Continuing Operations
-6m
GBP
-6m
GBP
Based on the financial report for Jun 30, 2023, Destiny Pharma PLC's Income from Continuing Operations amounts to -6m GBP.
What is Destiny Pharma PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-6%
-6%
Over the last year, the Income from Continuing Operations growth was 1%. The average annual Income from Continuing Operations growth rates for Destiny Pharma PLC have been -6% over the past three years .
You don't have any saved screeners yet
